• 1
    Ganzer R, Rogenhofer S, Walter B et al. PSA nadir is a significant predictor of treatment failure after high-intensity focussed ultrasound (HIFU) treatment of localised prostate cancer. Eur Urol 2008; 53: 54753
  • 2
    Uchida T, Illing RO, Cathcart PJ, Emberton M. To what extent does the prostate-specific antigen nadir predict subsequent treatment failure after transrectal high-intensity focused ultrasound therapy for presumed localized adenocarcinoma of the prostate? BJU Int 2006; 98: 5379
  • 3
    Gelet A, Chapelon JY, Bouvier R et al. Treatment of prostate cancer with transrectal focused ultrasound: early clinical experience. Eur Urol 1996; 29: 17483
  • 4
    Gelet A, Chapelon JY, Bouvier R, Pangaud C, Lasne Y. Local control of prostate cancer by transrectal high intensity focused ultrasound therapy: preliminary results. J Urol 1999; 161: 15662
  • 5
    Gelet A, Chapelon JY, Bouvier R et al. Transrectal high-intensity focused ultrasound: minimally invasive therapy of localized prostate cancer. J Endourol 2000; 14: 51928
  • 6
    ASTRO. Consensus Statement. Guidelines for PDSA following radiation therapy. Int J Radiat Oncol Biol Phys 1997; 37: 103541
  • 7
    Blana A, Rogenhofer S, Ganzer R et al. Eight years’ experience with high-intensity focused ultrasonography for treatment of localized prostate cancer. Urology 2008; 72: 132933
  • 8
    Blana A, Brown SC, Chaussy C et al. High intensity focused ultrasound for prostate cancer: comparative definitions of biochemical failure. BJU Int 2009; 104: 105862
  • 9
    D’Amico AV, Moul J, Carroll PR, Sun L, Lubeck D, Chen MH. Cancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostate-specific antigen era. J Clin Oncol 2003; 21: 216372
  • 10
    Blana A, Murat FJ, Walter B et al. First analysis of the long-term results with transrectal HIFU in patients with localised prostate cancer. Eur Urol 2008; 53: 1194201
  • 11
    Tsakiris P, Thüroff S, de la Rosette J, Chaussy C. Transrectal high-intensity focused ultrasound devices: a critical appraisal of the available evidence. J Endourol 2008; 22: 2219
  • 12
    Amling CL, Blute ML, Bergstralh EJ, Seay TM, Slezak J, Zincke H. Long-term hazard of progression after radical prostatectomy for clinically localized prostate cancer: continued risk of biochemical failure after 5 years. J Urol 2000; 164: 15
  • 13
    Hull GW, Rabbani F, Abbas F, Wheeler TM, Kattan MW, Scardino PT. Cancer control with radical prostatectomy alone in 1,000 consecutive patients. J Urol 2002; 167: 52834
  • 14
    Han M, Partin AW, Zahurak M, Piantadosi S, Epstein JI, Walsh PC. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol 2003; 169: 51723
  • 15
    Rosser CJ, Chichakli R, Levy LB, Kuban DA, Smith LG, Pisters LL. Biochemical disease-free survival in men younger than 60 years with prostate cancer treated with external beam radiation. J Urol 2002; 168: 53641
  • 16
    Kuban DA, Thames HD, Levy LB et al. Long-term multi-institutional analysis of stage T1-T2 prostate cancer treated with radiotherapy in the PSA era. Int J Radiat Oncol Biol Phys 2003; 57: 91528
  • 17
    Poissonnier L, Chapelon JY, Rouviere O et al. Control of prostate cancer by transrectal HIFU in 227 patients. Eur Urol 2007; 51: 3817
  • 18
    Neumayr A, Thueroff S, Nanieva R, Steil W, Leeser C, Chaussy C. PSA nadir development after local therapy by robotic high intensity focused ultrasound therapy (RHIFU) of T1-2 prostate cancer. J Endourol 2009; 23 (Suppl. 1): A175
  • 19
    Vallancien G, Prapotnich D, Cathelineau X, Baumert H, Rozet F. Transrectal focused ultrasound combined with transurethral resection of the prostate for the treatment of localized prostate cancer: feasibility study. J Urol 2004; 171(6 Pt 1): 22657
  • 20
    Jones JS, Rewcastle JC, Donnelly BJ, Lugnani FM, Pisters LL, Katz AE. Whole gland primary prostate cryoablation: initial results from the cryo on-line data registry. J Urol 2008; 180: 5548